All In Biotech

Drug Trial Radar · NCT06959225

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 580 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

580

Actual

Start

Jun 23, 2025

Primary completion

Oct 29, 2026

Study completion Jul 11, 2027

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
May 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • Ruxolitinib CreamDrug

    Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

  • Vehicle CreamDrug

    Matching vehicle cream applied topically to the affected area as a thin film twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baselineTime frame: Week 16

Locations

101 sites in 8 countries. Site status is shown where the registry gives one.

  • Investigative Site US020

    Phoenix, Arizona

  • Investigative Site US033

    Scottsdale, Arizona

  • Investigative Site US054

    Tempe, Arizona

  • Investigative Site US002

    Fayetteville, Arkansas

  • Investigative Site US055

    Brea, California

  • Investigative Site US004

    Laguna Niguel, California

  • Investigative Site US007

    Los Angeles, California

  • Investigative Site US013

    San Diego, California

  • Investigative Site US060

    San Diego, California

  • Investigative Site US038

    San Diego, California

  • Investigative Site US059

    Aurora, Colorado

  • Investigative Site US045

    Boynton Beach, Florida

  • Investigative Site US028

    Fort Myers, Florida

  • Investigative Site US016

    Miami, Florida

  • Investigative Site US027

    Sanford, Florida

  • Investigative Site US057

    Sweetwater, Florida

  • Investigative Site US029

    Tampa, Florida

  • Investigative Site US061

    Atlanta, Georgia

  • Investigative Site US053

    Atlanta, Georgia

  • Investigative Site US019

    Marietta, Georgia

  • Investigative Site US026

    Chicago, Illinois

  • Investigative Site US049

    Clarksville, Indiana

  • Investigative Site US052

    West Lafayette, Indiana

  • Investigative Site US001

    Bowling Green, Kentucky

  • Investigative Site US022

    Louisville, Kentucky

  • Investigative Site US050

    Baton Rouge, Louisiana

  • Investigative Site US046

    Glenn Dale, Maryland

  • Investigative Site US003

    Boston, Massachusetts

  • Investigative Site US030

    Boston, Massachusetts

  • Investigative Site US010

    Quincy, Massachusetts

  • Investigative Site US051

    Novi, Michigan

  • Investigative Site US006

    Minneapolis, Minnesota

  • Investigative Site US021

    New Brighton, Minnesota

  • Investigative Site US036

    Saint Joseph, Missouri

  • Investigative Site US034

    New City, New York

  • Investigative Site US018

    New York, New York

  • Investigative Site US017

    New York, New York

  • Investigative Site US023

    Rochester, New York

  • Investigative Site US014

    Chapel Hill, North Carolina

  • Investigative Site US025

    Fargo, North Dakota

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.